In an ambulatory patient without acute cardiac symptoms and a mildly elevated NT‑proBNP of 146 ng/L, what considerations should be made?

Mild NT-proBNP Elevation (146 ng/L) in Ambulatory Patients Without Cardiac Symptoms

An NT-proBNP of 146 ng/L in an ambulatory patient without acute cardiac symptoms represents "cardiac stress" and warrants systematic evaluation for subclinical cardiac dysfunction and optimization of cardiovascular risk factors, even though this level is below the traditional diagnostic threshold for heart failure.

Understanding the Clinical Significance

Your patient's NT-proBNP of 146 ng/L falls into an important gray zone. While this is below the standard diagnostic cutoff for heart failure (BNP ≥100 pg/mL or NT-proBNP ≥125-300 pg/mL depending on the clinical context) 1, it is not normal and should not be dismissed 2.

Recent consensus statements have introduced the concept of "cardiac stress" or "pre-heart failure" to describe this exact scenario: elevated NT-proBNP in asymptomatic patients with cardiovascular risk factors 2. This represents subclinical cardiac dysfunction and signals increased risk for progression to overt heart failure.

Immediate Clinical Actions

1. Risk Factor Assessment

Systematically evaluate for conditions that both elevate NT-proBNP and increase cardiovascular risk:

• Diabetes mellitus: NT-proBNP ≥125 pg/mL in diabetic patients identifies those at high risk for cardiac stress who may benefit from SGLT2 inhibitors 3, 4
• Hypertension: Check blood pressure control and consider intensification
• Chronic kidney disease: Assess eGFR (renal dysfunction elevates NT-proBNP independent of cardiac function) 5
• Atrial fibrillation: Review ECG and rhythm history (AF significantly elevates natriuretic peptides) 5
• Obesity: Note that obesity lowers NT-proBNP, so 146 ng/L in an obese patient may be more concerning than in a lean patient 5
• Peripheral arterial disease: PAD patients have elevated NT-proBNP even without cardiac symptoms 6
• Age and sex: Older age and female sex are associated with higher baseline levels 5

2. Echocardiography Consideration

While not emergent, consider outpatient echocardiography to assess for:

• Left ventricular systolic dysfunction
• Diastolic dysfunction/HFpEF
• Valvular disease (especially mitral regurgitation)
• Right ventricular dysfunction
• Pulmonary hypertension

The 2022 AHA/ACC/HFSA guidelines support using natriuretic peptide-based screening followed by team-based care including cardiovascular specialists to prevent development of LV dysfunction or new-onset HF (Class 2a recommendation) 1.

3. Therapeutic Optimization

For patients with diabetes and cardiac stress (NT-proBNP ≥125 pg/mL):

• Strongly consider initiating or ensuring treatment with SGLT2 inhibitors, which have proven mortality and heart failure benefits 3, 4
• More than 50% of diabetic patients with cardiac stress are not receiving SGLT2 inhibitors, representing a significant therapeutic gap 3

For all patients:

• Optimize blood pressure control (target <130/80 mmHg)
• Intensify statin therapy if indicated
• Ensure ACE inhibitor or ARB therapy if hypertensive or diabetic
• Address modifiable risk factors (smoking cessation, weight management, exercise)

Important Caveats and Pitfalls

Common Confounders to Consider:

• Pulmonary disease: COPD, pulmonary hypertension, or recent pulmonary embolism can elevate NT-proBNP through right ventricular strain 5
• Sepsis: Can cause elevation unrelated to chronic cardiac dysfunction 5
• Renal dysfunction: Reduced clearance elevates levels independent of cardiac stress 5
• Recent acute illness: May transiently elevate levels

Critical Point About "False Positives":

Elevated NT-proBNP in non-heart failure conditions should NOT be considered a "false positive" 7. These elevations reflect genuine pathological processes causing ventricular stress and are associated with adverse outcomes regardless of the underlying cause 7.

Prognostic Implications

Even mildly elevated NT-proBNP carries prognostic significance. The level of 146 ng/L indicates:

• Increased risk for developing overt heart failure
• Higher cardiovascular event risk
• Need for closer monitoring and aggressive risk factor modification

Studies demonstrate that NT-proBNP is useful for risk stratification in chronic heart failure and for screening patients at risk of developing HF 1.

Follow-Up Strategy

1. Repeat measurement in 3-6 months after optimizing risk factors to assess trajectory
2. Rising levels warrant more aggressive intervention and cardiology referral
3. Stable or declining levels suggest adequate risk factor control but continued monitoring
4. Consider the FIND-HF acronym for ongoing assessment: Fatigue, Increased water accumulation, Natriuretic peptide testing, Dyspnoea 2

The key message: this is not a normal result requiring no action, but rather an early warning signal demanding systematic cardiovascular risk assessment and optimization 2, 4.